Role of Hepatitis E Virus Infection in North American Patients With Severe Acute Liver Injury
Year: 2020
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: The aim of this study was to determine the role of hepatitis E virus (HEV) infection in a large cohort of prospectively enrolled patients with severe acute liver injury (ALI). METHODS: Serum samples from 594 consecutive adults enrolled between 2008 and 2018 in the US Acute Liver Failure Study Group ALI registry were tested for anti-HEV IgM and anti-HEV IgG levels. Those with detectable anti-HEV IgM underwent further testing for HEV RNA using real-time polymerase chain reaction. RESULTS: The median age of patients was 38 years; 41% were men and 72% Caucasian. Etiologies of ALI included acetaminophen hepatotoxicity (50%), autoimmune hepatitis (8.9%), hepatitis B virus (8.9%), and idiosyncratic drug-induced liver injury (7.9%). Overall, 62 patients (10.4%) were negative for anti-HEV IgM but positive for IgG, whereas only 3 men (0.5%) were positive for both anti-HEV IgM and IgG. These 3 cases were initially diagnosed as having indeterminate, HEV, and hepatitis B virus-related ALI. One of these patients had detectable HEV RNA genotype 3, and another anti-HEV IgM+ patient had detectable HEV antigens by immunohistochemistry on liver biopsy. On multivariate modeling, older (odds ratio: 1.99) and non-Caucasian subjects (odds ratio: 2.92) were significantly more likely to have detectable anti-HEV IgG (P < 0.0001). DISCUSSION: Acute HEV infection is an infrequent cause of ALI in hospitalized North American adults. The anti-HEV IgG+ patients were significantly older and more likely to be non-Caucasian. These data are consistent with other population-based studies that indicate exposure to HEV in the general US population is declining over time and might reflect a cohort effect.
Authors: Robert J. Fontana, Ronald E. Engle, Michelle Gottfried, Bilal Hammed, James Hanje, Valerie Durkalski, David E. Kleiner, Hanh Nguyen, Norihisa Nishimura, William M. Lee, Patrizia Farci, for the Acute Liver Failure Study Group
Institutions: University of Michigan, Michigan Medicine, National Institute of Allergy and Infectious Diseases, Medical University of South Carolina, University of California, San Francisco, The Ohio State University, National Institutes of Health, National Cancer Institute, The University of Texas Southwestern Medical Center
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,800
Funders: Bristol-Myers Squibb, Sanofi, Yale University, Gilead Sciences, Northwestern University, University of Washington, Mallinckrodt Pharmaceuticals, Southwestern Medical Foundation, Novo Nordisk, Genentech, University of California, San Francisco, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases
OpenAlex ID: W3101217433
